Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07527299 · ClinicalTrials.gov registry record · NA
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation
A NA study, sponsored by Biosense Webster.
- Recruiting
- Registry status
- NA
- Development phase
- 920
- Enrollment target
NCT07527299: Recruiting NA study, sponsored by Biosense Webster.
NCT07527299 is a NA study that is actively recruiting participants, run by Biosense Webster. The registered enrollment target is 920 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07527299, a NA study, is actively recruiting participants, sponsored by Biosense Webster.
- RECRUITING
- Registry status
- NA
- Development phase
- 920 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; PVI and SVCI), with or without another technique called posterior wall isolation (PWI). Also, to assess how safe it is for participants who are having a catheter ablation procedure and at the same time receiving another procedure called left atrial appendage occlusion (LAAO; to reduce stroke risk). Additionally, to assess how well VARIPULSE catheter system works over a long period of time for treatment of PsAF in participants undergoing catheter ablation.
Primary Outcome
PAEs include early onset AEs such as esophageal perforating complications, phrenic nerve paralysis (PNP; permanent), cardiac tamponade/perforation, pulmonary vein stenosis (PVS), death (device or procedure related), stroke/ cerebrovascular accident (CVA), major vascular access, complication/bleeding, thromboembolism, myocardial Infarction (MI), transient ischemic attack (TIA), pericarditis, pulmonary edema (respiratory insufficiency), heart block, and vagal nerve injury/ gastroparesis.
Interventions
- DEVICE VARIPULSE Catheter System
- DEVICE LAAO Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 920 participants |
| Start Date | 2026-08-05 |
| Est. Completion | 2031-08-04 |
| Phase | NA |
What NCT07527299 shows while recruiting
NCT07527299 is an interventional study that assigns participants to a tested intervention. The registered 920 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 2 interventions - of which VARIPULSE Catheter System is the first listed.
NCT07527299 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07527299 about?
NCT07527299 is a clinical study titled "A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation". The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and s...
What is the current status of trial NCT07527299?
This trial is currently recruiting. It is a NA study. The enrollment target is 920 participants. The study started on 2026-08-05. Estimated completion is 2031-08-04.
What interventions are being tested in trial NCT07527299?
The interventions under investigation include: VARIPULSE Catheter System (DEVICE), LAAO Device (DEVICE).
Who is sponsoring clinical trial NCT07527299?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07527299's enrollment target sits among peer trials
920 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04589845 · 920 participants · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT06109870 · 920 participants · NA
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
- NCT06957366 · 920 participants · NA
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
- NCT07174336 · 920 participants · Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI